Extragenital Mycoplasma hominis infection following obinutuzumab therapy in a patient with chronic lymphocytic leukemia
Abstract
Mycoplasma hominis is a fastidious, cell wall-deficient bacterium that typically colonizes the genitourinary tract but can cause invasive extragenital infections in immunocompromised hosts. Such infections have been reported primarily in patients receiving rituximab; however, they have not been previously described with obinutuzumab therapy. We report a case of M. hominis septic arthritis of the shoulder in a 70-year-old man with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with Obinutuzumab. The patient presented with several months of progressive shoulder pain and radiographic evidence of rapidly destructive arthritis. Repeated joint aspirations and early cultures were negative, and he required multiple surgical washouts because of extensive purulence and periarticular abscess formation. Extended incubation of synovial fluid and tissue cultures ultimately identified M. hominis. Antimicrobial therapy was transitioned to levofloxacin and doxycycline, which were administered for six weeks with good tolerance and sustained clinical improvement. At follow-up, the patient remained free of recurrent infection with gradual recovery of shoulder function. This case highlights M. hominis as an emerging opportunistic pathogen in patients receiving newer anti-CD20 monoclonal antibodies and expands the recognized infectious complications of obinutuzumab-induced B-cell depletion. Because M. hominis lacks a cell wall, routine diagnostic methods and empiric β-lactam…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.